46
Participants
Start Date
June 23, 2022
Primary Completion Date
April 30, 2025
Study Completion Date
November 30, 2025
Tislelizumab combined with Liposomal mitoxantrone hydrochloride
"Drug: liposomal mitoxantrone hydrochloride, tislelizumab Drug: Liposomal mitoxantrone hydrochloride (16 mg/m2, 20 mg/m2) will be administered by an intravenous infusion on day 1 of each 28-day cycle.~Drug: tislelizumab(200 mg) will be taken orally on day 1 of each 28-day cycle."
Maintenance of tislelizumab
Drug: tislelizumab(200 mg) will be taken orally on day 1 of each 21-day cycle
Beijing Tongren Hospital, Capital Medical University, Beijing
Peking Union Medical College Hospital, Beijing
The Second Hospital of Dalian Medical University, Dalian
Sun Yat-Sen University Cancer Center, Guangzhou
The First Affiliated Hospital/School of Clinical Medicine of Guangdong Pharmaceutical University, Guangzhou
Jiangxi Cancer Hospital, Nanchang
Sun Yat-sen University
OTHER